As of November 1, 2020, we will discontinue future development for Internet Explorer

To have a better experience, please upgrade to Microsoft Edge, Google Chrome, or Firefox. Sorry for the convenience.

Powering Precision
A Blog

Date:

New China operation

December 30th was an exciting day for NeoGenomics as we got the keys to our new facility in Suzhou, China. Suzhou is about 60 miles from Shanghai and is the new home for PPD and NeoGenomics newest…

Date:

CRO and Clinical Reference Laboratory Commercial Incentives

One of the challenges developing a companion diagnostic is creating a test that runs well in both clinical trials, and following regulatory approval, clinical testing laboratories Unfortunately, in…

Date:

Oncology Clinical Trials During a Pandemic

2020 has really been a year that doesn’t quit, hasn’t it? The dangerous part of COVID-19 has been how rapidly it has overwhelmed our healthcare system, in particular, how it has affected cancer…

Date:

It’s a Great Clinical Trial Assay

Can it be commercialized?

Date:

Is It Validated?

NeoGenomics has a menu of >600 assays across many different technologies and approaches. Clients often approach us after searching our menu online and ask if we can “Provide Test X for Clinical…

Date:

Liquid Biopsy Testing for PIK3CA Mutation

For years, researchers have looked into liquid biopsy as a potentially useful tool to help Health Care Providers assess a patient’s response to treatment, monitor cancer recurrence and even detect…

Date:

A spotlight on CDx development

NeoGenomics will share several posts focusing on CDx development. We will be launching an occasional updated blog covering our thoughts, musings, and opinions on personalized medicine.Or other topics…

Date:

Being Comprehensive in Hematologic Malignancies

The need for comprehensive testing seems obvious in the context of working up most cases of hematologic malignancies. However, there is still a perception gap amongst oncology providers of…

Date:

Improving Diagnosis of Barrett’s Esophagus

Esophageal cancer, while relatively uncommon, has risen dramatically over the past several decades. Currently it is the sixth most common cause of cancer deaths worldwide and its…

Date:

Expert approaches to resolving challenging areas in diagnostic pathology

Diagnostic conundrum: Classic Hodgkin Lymphoma or a mimic?
Close Menu